AU505355B2 - Sustained release formulation - Google Patents

Sustained release formulation

Info

Publication number
AU505355B2
AU505355B2 AU12049/76A AU1204976A AU505355B2 AU 505355 B2 AU505355 B2 AU 505355B2 AU 12049/76 A AU12049/76 A AU 12049/76A AU 1204976 A AU1204976 A AU 1204976A AU 505355 B2 AU505355 B2 AU 505355B2
Authority
AU
Australia
Prior art keywords
sustained release
release formulation
formulation
sustained
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU12049/76A
Other languages
English (en)
Other versions
AU1204976A (en
Inventor
P. R. Tossounian J. L Sheth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority claimed from KR7600645A external-priority patent/KR800001387B1/ko
Publication of AU1204976A publication Critical patent/AU1204976A/en
Application granted granted Critical
Publication of AU505355B2 publication Critical patent/AU505355B2/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus

Landscapes

  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU12049/76A 1975-03-17 1976-03-16 Sustained release formulation Expired AU505355B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55910775A 1975-03-17 1975-03-17
USUS559,107 1975-03-17
US65800376A 1976-02-13 1976-02-13
USUS658,003 1976-02-13
KR7600645A KR800001387B1 (en) 1975-03-17 1976-03-16 Process for preparing sustained release formulation

Publications (2)

Publication Number Publication Date
AU1204976A AU1204976A (en) 1977-09-22
AU505355B2 true AU505355B2 (en) 1979-11-15

Family

ID=27348140

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12049/76A Expired AU505355B2 (en) 1975-03-17 1976-03-16 Sustained release formulation

Country Status (21)

Country Link
JP (1) JPS51115910A (en:Method)
AR (1) AR222624A1 (en:Method)
AT (1) AT353415B (en:Method)
AU (1) AU505355B2 (en:Method)
CA (1) CA1073358A (en:Method)
CH (1) CH630257A5 (en:Method)
DD (1) DD124102A5 (en:Method)
DE (1) DE2611041A1 (en:Method)
DK (1) DK148344C (en:Method)
ES (1) ES446075A1 (en:Method)
FR (1) FR2304354A1 (en:Method)
GB (1) GB1546448A (en:Method)
GR (1) GR60341B (en:Method)
IE (1) IE43083B1 (en:Method)
LU (1) LU74558A1 (en:Method)
MC (1) MC1101A1 (en:Method)
NL (1) NL190313C (en:Method)
NZ (1) NZ180321A (en:Method)
PH (1) PH14927A (en:Method)
PT (1) PT64907B (en:Method)
SE (1) SE433804B (en:Method)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ197543A (en) * 1980-07-02 1984-12-14 Commw Scient Ind Res Org Controlled release compositions for inclusion in intraruminal devices
CH649215A5 (de) * 1981-04-29 1985-05-15 Hoffmann La Roche Pharmazeutische praeparate.
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
CH666406A5 (de) * 1984-02-29 1988-07-29 Sandoz Ag Verfahren zur herstellung von mikrokapseln, welche bromokriptinmesylat als pharmakologischen wirkstoff enthalten.
GB2154874B (en) * 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions
JPS61501511A (ja) * 1984-03-21 1986-07-24 アメリカン・ホ−ム・プロダクツ・コ−ポレイション 徐放性医薬カプセル
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
NL8600161A (nl) * 1985-02-05 1986-09-01 Sandoz Ag Farmaceutische preparaten die 9,10-dihydroergotalkaloiden bevatten.
GB8524135D0 (en) * 1985-10-01 1985-11-06 Sandoz Ltd Darodipine compositions
NL194822C (nl) * 1985-10-01 2003-04-03 Novartis Ag Preparaat voor orale toediening met geregelde afgifte en werkwijze voor de bereiding ervan.
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US4814178A (en) * 1987-07-01 1989-03-21 Sanford Bolton Floating sustained release therapeutic compositions
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
IE64128B1 (en) * 1990-02-26 1995-07-12 Byrne Rynne Holdings Ltd A pharmaceutical composition
DE69207656T2 (de) * 1991-01-30 1996-10-17 The Wellcome Foundation Ltd., London Wasserlösliche tabletten
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
US5498422A (en) * 1991-04-08 1996-03-12 Nippon Shinyaku Company Limited Sustained release capsule
DE69322077T2 (de) * 1992-03-25 1999-04-08 Depomed, Inc., Foster City, Calif. Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
US5888540A (en) * 1993-10-29 1999-03-30 Sugden; Keith Pharmaceutical products
WO1995011668A1 (en) * 1993-10-29 1995-05-04 Reckitt & Colman Products Limited Gelatin capsule fill able to foam
EP0725625B1 (en) * 1993-10-29 2000-03-22 R.P. Scherer Corporation Gelatin capsule fill able to foam
WO1995031186A1 (en) * 1994-05-13 1995-11-23 Smithkline Beecham Corporation Method and composition for increasing calcium uptake
CN1172429A (zh) * 1994-12-01 1998-02-04 希博斯药物公司 使用从高等植物中可得到的粉末状水解胶体树胶的持续释放药物运送体系
FR2820318B1 (fr) * 2001-02-08 2005-12-23 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant un principe actif et comprime obtenu
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
EP1245227A1 (en) 2001-03-31 2002-10-02 Jagotec Ag A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1059624B (de) * 1954-11-11 1959-06-18 Dr Knut Jacobus Sundman Verfahren zur Herstellung von in einer Traegersubstanz dispergierten Arzneien in dosierter Form
JPS5512411B2 (en:Method) * 1974-03-12 1980-04-02
DE2439538C3 (de) * 1974-08-17 1980-07-17 Ludwig Heumann & Co Gmbh, 8500 Nuernberg Verfahren zur Herstellung von oral zu verabreichenden Arzneimitteln mit verzögerter Wirkungsfreigabe

Also Published As

Publication number Publication date
NL190313C (nl) 1994-01-17
IE43083B1 (en) 1980-12-17
IE43083L (en) 1976-09-17
GR60341B (en) 1978-05-17
GB1546448A (en) 1979-05-23
NL7602776A (nl) 1976-09-21
FR2304354B1 (en:Method) 1979-04-27
NL190313B (nl) 1993-08-16
FR2304354A1 (fr) 1976-10-15
DE2611041A1 (de) 1976-10-14
JPS51115910A (en) 1976-10-13
DE2611041C2 (en:Method) 1988-06-09
PT64907A (fr) 1976-04-01
MC1101A1 (fr) 1977-02-04
AR222624A1 (es) 1981-06-15
PH14927A (en) 1982-01-29
DK113676A (da) 1976-09-18
PT64907B (fr) 1978-03-24
DK148344C (da) 1985-11-04
JPS638084B2 (en:Method) 1988-02-19
ES446075A1 (es) 1977-09-16
SE7603325L (sv) 1976-09-18
LU74558A1 (en:Method) 1977-09-27
CA1073358A (en) 1980-03-11
ATA192276A (de) 1979-04-15
SE433804B (sv) 1984-06-18
NZ180321A (en) 1978-06-20
DD124102A5 (en:Method) 1977-02-02
AT353415B (de) 1979-11-12
CH630257A5 (en) 1982-06-15
DK148344B (da) 1985-06-17
AU1204976A (en) 1977-09-22

Similar Documents

Publication Publication Date Title
AU505355B2 (en) Sustained release formulation
AU498744B2 (en) Release agent
AU508266B2 (en) Controlled release preparations
AU500958B2 (en) Shoe-sole configuration
AU497066B2 (en) Photocoplymerizable composition
AU504728B2 (en) Amidinoureas
AU1108376A (en) Polyhemoglobin
AU1025376A (en) Pourer-stopper
AU1006976A (en) Inhilator
AU503753B2 (en) Imidinoureas
AU500738B2 (en) Preparation
AU497446B2 (en) Composition
AU505076B2 (en) Banjo-shaped axle-casing
AU1128976A (en) Magneto-alternator
CA1020668A (en) Tritium-in-air monitor
AU511364B2 (en) Absorption-refrigerant composition
AU1191776A (en) Fluoro-prostaglandins
AU505910B2 (en) Neamatocidal composition
AU512445B2 (en) 4-hydroxymethyl-2-pyrrolidinones
AU497193B2 (en) Sprinkler
ZA761305B (en) Sustained release formulation
AU498384B2 (en) Anti-timor composition
AU1625476A (en) Aryltetralins
AU510864B2 (en) Halopregnadienes
AU495948B2 (en) Tablet formulation